Dapagliflozin enhanced the anticancer effects of the CTLA-4 blocking agent ipilimumab reducing its cardiotoxicity through galectine-3, Trimethylamine N-oxide (TMAO) and NLRP-3
Pulmonary hypertension in connective tissue diseases with overt of features of venous/capillaries involvement: clinical implications and prognostic impact of this phenotype.